Verana Health Raises $150M Series E Funding Round
Summary
Verana Health, a San Francisco, CA-based digital health company that delivers quality drug lifecycle and medical practice insights from an exclusive real-world data network, raised $150m in Series E funding. The round was led by Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and Novo Growth, the growth-stage investment arm of Novo Holdings with participation from existing investors GV (formerly Google Ventures), Casdin Capital, and Brook Byers, as well as new investors including the Merck Global Health Innovation Fund, THVC, and Breyer Capital. Jeffrey Low, MD, Principal at Novo Growth, and a representative from JJDC have joined Verana Health’s Board of Directors. The company intends to use the funds to advance its life sciences product and service strategy across the drug lifecycle, further enhance its value proposition to healthcare providers participating in its real-world data network, and expand its data footprint through medical society and strategic partnerships. Led by Sujay Jadhav, CEO, Verana Health is a digital health company committed to delivering quality drug lifecycle and medical practice insights from an exclusive real-world data network.